The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# **FORM D**

### OMB Number: Estimated average burden hours per response:

OMB APPROVAL

## **Notice of Exempt Offering of Securities**

1. Issuer's Identity				
CIK (Filer ID Number)	Previous Names	None	Entity Type	
0000887247	CELLEGY PH	ARMACEUTICALS INC	X Corporation	
Name of Issuer			Limited Partnership	
Adamis Pharmaceuticals Corp				
Jurisdiction of Incorporation/Or	ganization		Limited Liability Company	
DELAWARE			General Partnership	
Year of Incorporation/Organizat	ion		Business Trust	
X Over Five Years Ago			Other (Specify)	
Within Last Five Years (Sp	ecify Year)			
<b>=</b>	cony reary			
Yet to Be Formed				
2. Principal Place of Business	and Contact Information			
Name of Issuer				
Adamis Pharmaceuticals Corp				
Street Address 1		Street Address 2		
2658 DEL MAR HEIGHTS RD		#555		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer	
DEL MAR	CALIFORNIA	92014	(858) 401-3984	
3. Related Persons				
Last Name	First Name		Middle Name	
Carlos	Dennis		J.	
Street Address 1	Street Address 2			
2658 Del Mar Heights Road	#555			
City	State/Province/Co	untry	ZIP/PostalCode	
Del Mar	CALIFORNIA	•	92014	
Relationship: X Executive Off	cer X Director Promoter			
Clarification of Response (if Ne	cessary):			
Last Name	First Name		Middle Name	
Marguglio	David		J.	
Street Address 1	Street Address 2			
2658 Del Mar Heights Road	#555			
City	State/Province/Co	untry	ZIP/PostalCode	
Del Mar	CALIFORNIA		92014	
Relationship: X Executive Off				
Clarification of Response (if Ne	cessary):			
Last Name	First Name		Middle Name	
Hopkins	Robert		O.	
Street Address 1	Street Address 2		<b>O.</b>	
2658 Del Mar Heights Road	#555			
Der man rierging Road				

City	State/Province/Country	ZIP/PostalCode	
Del Mar	CALIFORNIA	92014	
Relationship: X Executive Officer X Director Promoter			
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Aloi	Richard	L.	
Street Address 1	Street Address 2		
2658 Del Mar Heights Road	#555		
City	State/Province/Country	ZIP/PostalCode	
Del Mar	CALIFORNIA	92014	
Relationship: X Executive Officer X Direct	ctor Promoter		
Clarification of Response (if Necessary):			
4. Industry Group			
Agriculture	Health Care	Detailing.	
Banking & Financial Services		Retailing	
	Biotechnology	Restaurants	
Commercial Banking	Health Insurance	Technology	
Insurance	Hospitals & Physicians	Computers	
Investing			
Investment Banking	X Pharmaceuticals	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
Is the issuer registered as	Manufacturing	Travel	
an investment company under	Real Estate	Airlines & Airports	
the Investment Company Act of 1940?	Commercial	Allines & Allports	
		Lodging & Conventions	
YesNo	Construction	Tourism & Travel Services	
Other Banking & Financial Services	REITS & Finance		
Business Services		Other Travel	
Energy	Residential	Other	
Coal Mining	Other Real Estate	_	
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
Other Energy			
5. Issuer Size			
Revenue Range OR	Aggregate Net Asset Va	ılue Range	
No Revenues	No Aggregate Net As	-	
X \$1 - \$1,000,000	\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000	000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,00	U,UUU	
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,0	.00,000	
Over \$100,000,000	Over \$100,000,000		
Decline to Disclose	Decline to Disclose		
<b>□</b>	ш=====================================		

Not Applicable	Not Applicable				
6. Federal Exemption(s) and Exclusion(s) Claim	ed (select all that apply)				
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	X   Rule 505   X   Rule 506   Securities Act Section 4(5)   Investment Company Act Section 3(c)   Section 3(c)(1)   Section 3(c)(9)   Section 3(c)(2)   Section 3(c)(10)   Section 3(c)(3)   Section 3(c)(11)   Section 3(c)(4)   Section 3(c)(12)   Section 3(c)(5)   Section 3(c)(13)   Section 3(c)(6)   Section 3(c)(14)   Section 3(c)(7)				
7. Type of Filing					
Amendment	First Sale Yet to Occur				
8. Duration of Offering					
Does the Issuer intend this offering to last more that	an one year? Yes X No				
9. Type(s) of Securities Offered (select all that ap	pply)				
<ul> <li>X Equity</li> <li>Debt</li> <li>Option, Warrant or Other Right to Acquire Anoth</li> <li>Security to be Acquired Upon Exercise of Option</li> <li>Right to Acquire Security</li> </ul>					
10. Business Combination Transaction					
Is this offering being made in connection with a bus merger, acquisition or exchange offer?  Clarification of Response (if Necessary):  11. Minimum Investment	siness combination transaction, such as a Yes X No				
Minimum investment accepted from any outside in	vestor \$0 USD				
12. Sales Compensation					
Check "All States" or check individual States	Recipient CRD Number X None  (Associated) Broker or Dealer CRD Number X None  Street Address 2  State/Province/Country  ZIP/Postal Code  Il States  Foreign/non-US				
13. Offering and Sales Amounts					
Total Offering Amount \$5,000,000 USD or Total Amount Sold \$0 USD	Indefinite				

Total Remaining to be Sold \$5,000,000 USD or Indefinite	
Clarification of Response (if Necessary):	
14. Investors	
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.	
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:	1
15. Sales Commissions & Finder's Fees Expenses	
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not estimate and check the box next to the amount.	known, provide an
Sales Commissions \$0 USD Estimate	
Finders' Fees \$0 USD Estimate	
Clarification of Response (if Necessary):	
16. Use of Proceeds	
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the per be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimbox next to the amount.	
\$745,000 USD X Estimate	
Clarification of Response (if Necessary):	
Signature and Submission	
Please verify the information you have entered and review the Terms of Submission below before signing and clicking	SUBMIT below to

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### **Terms of Submission**

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Adamis Pharmaceuticals Corp	Robert O. Hopkins	/s/Robert O. Hopkins	Chief Financial Officer	2010-11-23

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

<sup>\*</sup> This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.